

NEW DRUGS

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录  
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

中国新药杂志  
二〇一九年  
第二十八卷  
第十七期  
第2049-2176页  
半月刊

CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6

# 中国新药杂志



17  
2019  
Vol.28 | No.17

- 从知识价值链视角看藏药新药研发策略
- 羟苯苄酯含量测定能力验证研究
- 脂质运载蛋白型前列腺素D合成酶作为难溶性药物给药载体的研究进展
- 《创新药（化学药）Ⅲ期临床试验药学研究信息指南》解读
- HPLC-MS/MS法测定人血浆中儿茶酚胺浓度的方法学建立
- 中药板蓝根提取液致细胞增殖的研究

www.newdrug.cn

ISSN 1003-3734



国家药品监督管理局主管



万方数据

## •新药述评与论坛•

- 2049 从知识价值链视角看藏药新药研发策略.....陈维武, 孙利华
- 2056 基于临床价值的藏药二次开发策略——以藏药青鹏软膏为例.....陈维武, 孙利华
- 2063 专利信息视角下中国抗白血病药的研发状况.....孙慧, 董丽
- 2069 贝利司他药物专利分析.....周付科, 郭晓赟, 迟丽娜, 等

## •重大新药创制专项巡礼•

- 2076 羟苯苄酯含量测定能力验证研究.....杨锐, 许凯, 王珏, 等
- 2081 人参附子及其有效成分配伍对心脏表氧化酶CYP2J3、羟化酶CYP4A3和CYP4F11 mRNA表达的影响.....孙佳, 张广平, 苏萍, 等

## •综述•

- 2089 脂质运载蛋白型前列腺素D合成酶作为难溶性药物给药载体的研究进展.....范磊, 田霞, 张胜男, 等
- 2095 免疫检查点抑制剂相关心肌炎研究进展.....徐伟仙, 李海燕
- 2100 多发性硬化治疗药物非临床药效学评价.....单晓蕾, 王庆利, 黄芳华

## •药物临床试验质量管理和提升专栏•

- 2106 《创新药(化学药) III期临床试验药学研究信息指南》解读.....任连杰, 周浩辉, 张宁, 等
- 2113 健全药物临床试验期间安全性数据快速报告制度及加强临床试验风险监测管理.....裴小静, 韩玲, 王涛
- 2117 抗肿瘤药物首次临床试验起始剂量的一般考虑.....叶旋, 张旻, 闫莉萍, 等

## •临床研究•

- 2120 HPLC-MS/MS法测定人血浆中儿茶酚胺浓度的方法学建立.....李泰锋, 刘雪梅, 胡蕾, 等
- 2126 脑血疏口服液治疗脑卒中后脑水肿的多中心随机对照临床研究.....郭振宇, 张毅, 代永庆, 等
- 2130 丁苯酞注射液联合双联抗血小板治疗穿支动脉疾病型脑梗死的疗效.....郑丽, 李虹, 陈娜, 等

## •实验研究•

- 2135 中药板蓝根提取液致细胞增殖的研究.....吴彦霖, 张媛, 刘俊, 等
- 2141 基于主成分分析和多指标综合指数法研究丹参-三七药对活血化瘀作用量效关系.....陶慧娟, 乐世俊, 唐于平, 等
- 2148 基于反向分子对接和网络药理学确定冬凌草甲素抗肿瘤的潜在作用机制.....刘伟, 张彦忠, 白素平
- 2157 他达拉非口腔速溶膜的临床前药动学研究.....陈小云, 秦燕, 肖峰, 等

## •药物安全与合理应用•

- 2163 陕西地区云南白药胶囊临床安全性集中监测研究.....邓岳, 张辽辽, 李博, 等
- 2170 曲克芦丁脑蛋白水解物注射液治疗脑梗死的系统评价与Meta分析.....张晖, 张华, 刘平, 等

- 2049 The research and development strategy of tibetan new drugs from the perspective of knowledge value chain  
CHEN Wei-wu, SUN Li-hua
- 2056 The secondary development strategy of Tibetan medicine based on clinical value: taking Qingpeng ointment as an example  
CHEN Wei-wu, SUN Li-hua
- 2063 Research and development of anti-leukemia drugs in China from perspective of patent information  
SUN Hui, DONG Li
- 2069 Analysis of the patents of belinostat  
ZHOU Fu-ke, GUO Xiao-yun, CHI Li-na, *et al*
- 2076 Proficiency-testing of determination for benzyl hydroxybenzoate contents  
YANG Rui, XU Kai, WANG Jue, *et al*
- 2081 Effects of ginseng aconite and its effective components combination on the mRNA's expression of oxidase CYP2J3 hydroxylase, CYP4A3 and CYP4F11  
SUN Jia, ZHANG Guang-ping, SU Ping, *et al*
- 2089 Advances in using lipocalin-type prostaglandin D synthase as delivery carrier for poorly water-soluble drugs  
FAN Lei, TIAN Xia, ZHANG Sheng-nan, *et al*
- 2095 Research progress of immune checkpoint inhibitor related myocarditis  
XU Wei-xian, LI Hai-yan
- 2100 Nonclinical efficacy of multiple sclerosis modify drugs  
SHAN Xiao-lei, WANG Qing-li, HUANG Fang-hua
- 2106 Interpretation of Guidance on CMC Study of Investigational New Chemical Drug Applications for Phase III Clinical Trial  
REN Lian-jie, ZHOU Hao-hui, ZHANG Ning
- 2113 Enhancing the system of expedited reporting of safety data during clinical trials of drugs and strengthening the management of clinical trial risk monitoring  
PEI Xiao-jing, HAN Ling, WANG Tao
- 2117 General considerations on first-in-human dose estimation for anti-cancer drug clinical trials  
YE Xuan, ZHANG Min, YAN Li-ping, *et al*
- 2120 Establishment of a LC/MS/MS method to determine content of catecholamines in human plasma  
LI Tai-feng, LIU Xue-mei, HU Lei, *et al*
- 2126 A multicenter, randomized, controlled clinical trial for application of Naoxueshu oral liquid in the treatment of cerebral edema after stroke  
GUO Zhen-yu, ZHANG Yi, DAI Yong-qing, *et al*
- 2130 Preliminary efficacy of butylphthalide combined with dual antiplatelet drugs in patients with perforating artery cerebral infarction  
ZHENG Li, LI Hong, CHEN Na, *et al*
- 2135 Evaluating effects of *Radix Isatidis* extraction on cell proliferation  
WU Yan-lin, ZHANG Yuan, LIU Jun, *et al*
- 2141 Analyzing dose-effect relation of Danshen-Sanqi herb pair for promoting blood circulation and removing blood stasis effects by PCA and multi-attribute comprehensive index methods  
TAO Hui-juan, YUE Shi-jun, TANG Yu-ping, *et al*
- 2148 Possible anticancer mechanism of oridonin determined by reverse molecular docking and network pharmacological technology  
LIU Wei, ZHANG Yan-zhong, BAI Su-ping
- 2157 Preclinical pharmacokinetic study of tadalafil oral fast dissolving films  
CHEN Xiao-yun, QIN Yan, XIAO Feng, *et al*
- 2163 Centralized monitoring of clinical safety of Yunnan Baiyao capsules in Shanxi and Ningxia region  
DENG Yue, ZHANG Liao-liao, LI Bo, *et al*
- 2170 Efficacy and safety of troxerutin and cerebroprotein hydrolysate injection on acute cerebral ischemic stroke: a systematic review and Meta-analysis  
ZHANG Hui, ZHANG Hua, LIU Ping, *et al*

**Directed by:** National Medical Products Administration  
**Sponsored by:** China Medical Science Press  
China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association  
**Editor-in-Chief:** SANG Guo-wei  
**Board Chairman:** SHI Sheng-yi  
**Edited by:** Editorial Board of Chinese Journal of New Drugs  
**Published by:** Chinese Journal of New Drugs Co., Ltd.  
**Address:** Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China  
**Tel:** (010)52722697 / 52722651 / 52723707

**Website:** <http://www.newdrug.cn>  
**E-mail:** [bianjibu@newdrug.cn](mailto:bianjibu@newdrug.cn)  
**Printer:** Beijing Kexin Printing Co., Ltd.  
**Domestic Distribution:** Beijing Post Offices  
**Overseas Distribution:** China International Book Trading Corp.  
(P.O.Box 399 Beijing, China)  
**Domestic Subscription:** Local Post Offices  
**Periodical Registration:** ISSN 1003-3734 CN 11-2850/R  
**Publication Date:** September 15, 2019  
**Copyright:** 2019 by Chinese Journal of New Drugs Co.,Ltd.